SOUTHWEST ONCOLOGY GROUP

西南肿瘤集团

• 批准号: 7363699
• 负责人: THOMAS Patrick MILLER
• 金额: $ 26.65万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7363699
• 关键词: ABCB1 gene; Academic Medical Centers; Accreditation; Acute; Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Acute Promyelocytic Leukemia; Address; Adenosquamous carcinoma; Adherence; Adjuvant; Adjuvant Therapy; Administrator; Adult; Adverse Drug Experience Report; Adverse event; Affect; Aftercare; Age; Age Factors; Agreement; Allogenic; Altretamine; American; American Society of Clinical Oncology; Amifostine; Ancillary Study; Anemia; Angiogenic Factor; Anthracycline Antibiotics; Anthracyclines; Antibiotics; Antibodies; Antibody Therapy; Antigens; Antineoplastic Agents; Apoptosis; Applications Grants; Ara-C; Arabia; Area; Arizona; Art Therapy; Arts; Attenuated; Atypical Endometrial Hyperplasias; Authorship; Autologous; Autologous Transplantation; Award; Awareness; Azotemia; B-Cell Lymphomas; B-Cell NonHodgkins Lymphoma; B-Lymphocytes; Back; Basic Science; Beds; Behavioral Sciences; Bilirubin; Bioinformatics; Biological; Biological Assay; Biological Markers; Biology; Biometry; Biopsy; Blast Phase; Bleomycin/Cytarabine/Methotrexate/Vincristine; Blood; Blood Vessels; Blood specimen; Bone Marrow; Bone Marrow Stem Cell Transplantation; Bone Marrow Transplantation; Brain Neoplasms; Breast; Breast Cancer Prevention Trial; Bronchoscopy; Budgets; CSF3 gene; Calcium; Calculi; California; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Control Research; Cancer Information Service; Cancer Patient; Cancer Prevention Trial; Cancer Trials Support Unit; Cancer Vaccines; Cancer and Leukemia Group B; Carboplatin; Carboplatin/Etoposide; Carboplatin/Paclitaxel; Carcinoma; Cardiac; Cardiovascular system; Cell Line; Cell Proliferation; Cell Therapy; Cell physiology; Cell surface; Cells; Cervical dysplasia; Cervix Uteri; Cervix carcinoma; Cessation of life; Chairperson; Chemoprevention; Chemotherapy-Oncologic Procedure; Chest; Children' s Oncology Group; Chronic Myeloid Leukemia; Cisplatin; Cisplatin/Dacarbazine/Interferon Alfa/Tamoxifen; Classification; Clinic; Clinical; Clinical Cancer Center; Clinical Data; Clinical Immunology; Clinical Management; Clinical Medicine; Clinical Pharmacology; Clinical Protocols; Clinical Research; Clinical Research Associate; Clinical Services; Clinical Trials; Clinical Trials Cooperative Group; Closure; Collaborations; Colon Carcinoma; Colorado; Colorectal; Colorectal Cancer; Combination Chemotherapy; Combined Modality Therapy; Commit; Committee Members; Committee Membership; Communication; Communities; Community Clinical Oncology Program; Community Outreach; Complement; Complex; Compound 506U78; Comprehensive Cancer Center; Conflict (Psychology); Consent; Consent Forms; Consult; Consultations; Continuous Infusion; Continuous Intravenous Infusion; Cooperative Group Program; Core Facility; Correlation Studies; Counseling; Coupled; Cyclin D1; Cyclins; Cyclophosphamide; Cyclophosphamide/Dexamethasone/Doxorubicin/Verapamil/Vincristine; Cyclosporine; Cyclosporins; Cytarabine; Cytogenetics; DNA; DNA Adduction; DNA Microarray Chip; DNA Microarray format; DNA amplification; Daily; Data; Data Analyses; Data Quality; Databases; Daunorubicin; Dendritic Cells; Depo Provera; Detection; Development; Developmental Therapeutics Program; Devices; Dexamethasone; Diagnosis; Diagnostic; Diagnostic Neoplasm Staging; Diagnostic Procedure; Diagnostic radiologic examination; Diffuse; Diffuse Lymphoma; Disadvantaged; Discipline; Discipline of Nuclear Medicine; Discipline of obstetrics; Disease; Disease remission; Disorder by Site; Distant Metastasis; Division of Cancer Biology; Doctor of Medicine; Doctor of Philosophy; Documentation; Donor person; Dose; Doxorubicin; Doxorubicin Hydrochloride Liposome; Doxorubicin/Vinblastine; Drug Delivery Systems; Drug Kinetics; Drug resistance; Dysmyelopoietic Syndromes; ERBB2 gene; Early treatment; Eastern Cooperative Oncology Group; Education and Outreach; Elderly; Electronics; Eligibility Determination; Emergency Situation; Endometrial Carcinoma; Endometrial Hyperplasia; Endometrial adenocarcinoma; Endothelial Growth Factors; Enrollment; Ensure; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Epithelial; Epithelial ovarian cancer; Erythrocytes; Erythropoietin; Etoposide; Etoposide/Mitoxantrone; European; Evaluation; Event; Excision; Exercise; Experimental Designs; Extramural Activities; Faculty; Failure; Family; Family member; Feasibility Studies; Feedback; Fellowship Program; Fibroblast Growth Factor; Floor; Fludarabine/Mitoxantrone; Fluorouracil; Focus Groups; Follicular Lymphoma; Follow-Up Studies; Foundations; Freezing; Frozen Sections; Funding; Funding Applicant; Future; Gastroenterology; Gastrointestinal Neoplasms; Gelatinase A; Gelatinase B; Gene Expression; Gene Expression Profile; Gene Expression Profiling; Gene Targeting; Generations; Genes; Genetic; Genetic Research; Genitourinary system; Germany; Glass; Glucocorticoids; Glycoproteins; Goals; Goserelin; Grant; Growth Factor; Growth Factor Receptors; Guidelines; Gynecologic; Gynecologic Oncology; Gynecologic Oncology Group; Gynecologist; Gynecology; HLA-DR Antigens; Head; Head and Neck Cancer; Head and neck structure; Health; Health Professional; Health Sciences; Healthcare; Heart-Lung Transplantation; Helicobacter pylori; Hematologic Neoplasms; Hematology; Hematopathology; Hematopoietic; Hematopoietic Neoplasms; High Dose Chemotherapy; Hispanics; Histocompatibility; Histocompatibility Antigens; Histocompatibility Antigens Class II; Histologic; Histology; Hodgkin Disease; Home environment; Homologous Transplantation; Hospitals; Hour; Housing; Human; Human Papillomavirus; Human Resources; Hyperplasia; Hysterectomy; I131 isotope; Image; Imaging technology; Immune; Immune response; Immunobiology; Immunohistochemistry; Immunophenotyping; Immunotherapy; In Vitro; In complete remission; Incidence; Individual; Industry; Infusion procedures; Inpatients; Institutes; Institution; Interdisciplinary Study; Interferon Alfa-2a; Interferon Alfa-2b; Interferon Type II; Interferon-alpha; Interferons; Interleukin-4; Interleukin-6; Interleukins; Internal Medicine; International; Internet; Intervention; Intraepithelial Neoplasia; Intraoperative Monitoring; Intravenous; Investigation; Investigational Drugs; Isotretinoin; Japan; Joints; Journals; Ki-1 Large-Cell Lymphoma; L-17M protocol; Laboratories; Laboratory Research; Laboratory Study; Lactate Dehydrogenase; Laparotomy; Large Intestine Carcinoma; Lasers; Lead; Leadership; Local Therapy; Localized; Localized Disease; Lung; Lymph; Lymph node excision; Lymphatic Irradiation; Lymphedema; Lymphoblastic Leukemia; Lymphoma; Lymphoproliferative Disorders; MLH1 gene; MS4A1 gene; MSH2 gene; Magnetic Resonance Imaging; Maintenance; Maintenance Therapy; Major Histocompatibility Complex; Malignant - descriptor; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant Pleural Mesothelioma; Malignant neoplasm of brain; Malignant neoplasm of cervix uteri; Malignant neoplasm of esophagus; Malignant neoplasm of fallopian tube; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of kidney; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Mammalian Oviducts; Mantle Cell Lymphoma; Manuscripts; Marrow; Marshal; Master of Public Health; Matrix Metalloproteinases; Measurement; Mediastinoscopy; Medical; Medical Oncologist; Medical Oncology; Medical center; Medicine; Medroxyprogesterone 17-Acetate; Melphalan; Membrane; Menogaril; Mentors; Mesothelioma; Meta-Analysis; Metastatic Melanoma; Mexico; Microdissection; Microsatellite Instability; Minority; Minority Outreach Program; Mitoxantrone; Modality; Modeling; Modification; Molecular; Molecular Classification of Tumors; Molecular Diagnosis; Molecular Genetics; Molecular Profiling; Molecular and Cellular Biology; Monitor; Moon; Morphology; Morus; Multi-Drug Resistance; Multicenter Studies; Multidrug Resistance-Associated Proteins; Multimodal Imaging; Multiple Myeloma; Myelogenous; Myeloid Leukemia; N(delta)-acetylornithine, -isomer; N-dodecanoylglutamic acid, -isomer, sodium salt; NCI Center for Cancer Research; National Cancer Institute; National Surgical Adjuvant Breast and Bowel Project; Native Americans; Nature; Navelbine ditartrate; Neoadjuvant Therapy; Neoplasm Metastasis; Nephrectomy; New Agents; New Mexico; Newly Diagnosed; No Evidence of Disease; Nodal; Non-Hodgkin' s Lymphoma; Non-Small-Cell Lung Carcinoma; North America; Numbers; Nurse Practitioners; Nurses; Nursing Faculty; Nursing Research; Nutritional; Obstetrics Departments; Ocular Melanoma; Oligonucleotides; Oncogene Proteins; Oncogenic; Oncologist; Oncology Group; Operating Room Nursing; Operating Rooms; Operative Surgical Procedures; Oral; Orchiectomy; Organ; Other Resources; Outcome; Outpatients; Ovarian; Ovarian Carcinoma; Ovariectomy; PTGS2 gene; Paclitaxel; Pain management; Paper; Paramedical Personnel; Participant; Pathogenesis; Pathologist; Pathology; Pathway interactions; Patient Appointment; Patient Care; Patient Education; Patient Recruitments; Patients; Pattern; Pediatric Oncology Group; Pelvis; Performance; Peripheral Blood Stem Cell; Peripheral Stem Cell Transplant; Peripheral Stem Cell Transplantation; Peritoneal; Personal Satisfaction; Persons; Pharmaceutical Preparations; Pharmacists; Pharmacology; Pharmacology and Toxicology; Pharmacy facility; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Phase III Clinical Trials; Phenotype; Philadelphia; Physical Chemistry; Physician Assistants; Physician Executives; Physicians; Physics; Pilot Projects; Piper; Placebos; Plan B; Platinum; Play; Pleural; Policies; Politics; Polymerase Chain Reaction; Population; Population Study; Positioning Attribute; Positron-Emission Tomography; Postoperative Period; Precancerous Conditions; Prednisone; Premenopause; Preparation; Prevention; Prevention Protocols; Prevention program; Preventive; Primary Neoplasm; Principal Investigator; Private Practice; Procedures; Process; Productivity; Prognostic Factor; Program Development; Program Research Project Grants; Progression-Free Survivals; Proliferative Index; Prospective Studies; Prostate; Prostate Cancer Prevention Trial; Prostatic; Prostatic Intraepithelial Neoplasias; Protein Chemistry; Protein Overexpression; Proteins; Protocols documentation; Public Health; Publications; Published Comment; Publishing; Purines; Purpose; Quality Control; Quality of Care; Quinine; RSR-13; Radiation; Radiation Oncology; Radiation Therapy Oncology Group; Radiation therapy; Radioimmunoconjugate; Radiosurgery; Randomized; Randomized Clinical Trials; Randomized Controlled Clinical Trials; Range; Rate; Raven; Receptor Protein-Tyrosine Kinases; Recombinants; Recording of previous events; Recovery; Recruitment Activity; Recurrence; Recurrent disease; Refractory; Regional Cancer; Regulation; Rehabilitation therapy; Relapse; Remission Induction; Renal Cell Carcinoma; Renal carcinoma; Reporting; Reproduction spores; Research; Research Design; Research Ethics Committees; Research Infrastructure; Research Personnel; Research Project Grants; Research Proposals; Research Support; Resected; Residencies; Residual state; Resistance; Resources; Retinoids; Retrospective Studies; Review Committee; Review Literature; Rice; Risk; Risk Factors; Role; Running; Rural Community; SCID Mice; SDZ-PSC-833; Salmon; Sampling; Schedule; Science; Scientist; Second Look Surgery; Selenium; Seminoma; Series; Serum; Services; Signal Transduction; Site; Skin Cancer; Smoker; Societies; Solid; Solid Neoplasm; Source; Southwest Oncology Group; Specific qualifier value; Specimen; Staging; Standards of Weights and Measures; Stem cell transplant; Stem cells; Stomach Carcinoma; Strategic Planning; Structure; Structure of germinal center of lymph node; Subgroup; Supportive care; Surgical Oncology; Suspension substance; Suspensions; Syndrome; System; Systemic Therapy; T-Lymphocyte; TP53 gene; Techniques; Telemedicine; Testing; Text; Thalidomide; Therapeutic; Therapeutic Effect; Therapeutic Index; Therapeutic procedure; Thioredoxin; Thoracic Oncology; Thoracic Surgical Procedures; Time; Tissue Inhibitor of Metalloproteinase-1; Tissue Procurements; Tissues; Topotecan; Toxic effect; Toxicology; Transfusion; Translational Research; Translations; Transplantation; Treatment Failure; Treatment Protocols; Tretinoin; Triplet Multiple Birth; Tumor Biology; Tumor Debulking; Tumor Markers; Tumor Suppressor Proteins; Universities; Update; Upper arm; Urogenital Cancer; Urologic Cancer; Urologic Surgeon; Urology; Utah; Variant; Vascular Endothelial Cell; Vascular Endothelial Growth Factor Receptor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factors; Verapamil; Videoconferences; Videoconferencing; Vinblastine; Vinorelbine; Vinorelbine tartrate; Virginia; Visit; Waldenstrom Macroglobulinemia; Week; Whole-Body Irradiation; Wing; Wolves; Woman; Work; Writing; X-Ray Computed Tomography; Y 90 Ibritumomab Tiuxetan; ZD1839 (IRESSA); abstracting; adenoma; alpha-difluoromethyl-DOPA, -isomer; alpha-methylornithine dihydrochloride, -isomer; angiogenesis; anticancer research; antigene; assay development; authority; autocrine; base; beta Globin; bevacizumab; bleomycin/dacarbazine/doxorubicin/vinblastine protocol; cancer care; cancer cell; cancer imaging; cancer prevention; cancer research center director; cancer surgery; cancer therapy; celecoxib; cell growth; cellular targeting; chemosensitizing agent; chemotherapy; cisplatin/etoposide protocol; clinical Diagnosis; college; computerized; concept; cyclin D2; cyclin D3; cyclophosphamide/doxorubicin/etoposide/methotrexate/prednisone protocol; dalton; day; density; design; disorder control; drug development; drug discovery; drug testing; experience; fludarabine; follow-up; foot; gastroesophageal junction adenocarcinoma; gastrointestinal; gene therapy; genetic risk assessment; graft vs host disease; hatching; high risk men; histiocyte; human subject; ilium; immunopathology; implementation research; improved; indexing; inhibitor/antagonist; insight; interdisciplinary collaboration; interest; intraepithelial; intraperitoneal; intraperitoneal therapy; iodine-131-tositumomab; irradiation; large cell Diffuse non-Hodgkin' s lymphoma; leukemia; leukemia/lymphoma; leukemogenesis; major vault protein; malignant breast neoplasm; malignant stomach neoplasm; medical specialties; melanoma; member; men; metropolitan; molecular oncology; mucosa-associated lymphoid tissue lymphoma; multidisciplinary; named group; neoplastic; neoplastic cell; neuro-oncology; novel; novel strategies; novel therapeutics; older patient; oncology; outcome forecast; outreach; outreach program; paracrine; performance status 2; peritoneal cancer; pilot trial; prevent; professor; progenitor; progesterone 11-hemisuccinate-(2-iodohistamine); prognostic; programs; promoter; prospective; protocol development; purine; quality assurance; receptor; receptor expression; recombinant human erythropoietin; repository; reproductive function; research clinical testing; response; rituximab; sarcoma; scientific organization; skin cancer prevention; success; symposium; technology development; tirapazamine; tositumomab; treatment program; trend; trial comparing; tumor; tumor growth; tumor progression; tumorigenic; vaccine development

DESCRIPTION (provided by applicant): Funding is requested to support Arizona Cancer Center (University of Arizona) participation in Southwest Oncology Group (SWOG) cooperative cancer clinical research to improve the treatment of cancer in humans. Specific aims and objectives are: 1. To continue to meet our current scientific leadership and core service commitments including: (a) protocol coordination (multiple studies); (b) disease and discipline committee administration; (c) reference and repository laboratory administration; (d) group quality assurance and quality control. 2. To continue to promote the rapid integration of promising new research leads, including those developed at the Arizona Cancer Center, into cooperative group testing to improve patient treatment options and patient care. 3. To continue to meet our institutional clinical research commitments in the recruitment of appropriate patients for SWOG and SWOG-endorsed studies and all attendant commitments to Iong-term follow-up, quality assurance, quality control, etc. 4. To continue to promote physician and patient awareness of and participation in SWOG and SWOG-endorsed clinical trials and outreach programs. 5. To continue efforts to understand factors affecting accrual, particularly those in special populations (e.g., minority, elderly, financially disadvantaged), and to implement appropriate interventions where possible.

描述(由申请者提供)：申请资助以支持亚利桑那癌症中心(亚利桑那大学)参与西南肿瘤学集团(SWOG)合作的癌症临床研究，以改善人类癌症的治疗。具体的目标和目标是： 1.继续履行我们目前的科学领导和核心服务承诺，包括：(A)方案协调(多项研究)；(B)疾病和纪律委员会管理；(C)参考和资料库实验室管理；(D)团体质量保证和质量控制。 2.继续推动将有希望的新研究线索，包括亚利桑那州癌症中心开发的那些，迅速整合到合作的团体测试中，以改善患者的治疗选择和患者护理。 3.继续履行我们的机构临床研究承诺，为SWOG和SWOG认可的研究招募合适的患者，以及所有随之而来的长期随访、质量保证和质量控制等承诺。 4.继续促进医生和患者对SWOG和SWOG批准的临床试验和推广计划的认识和参与。 5.继续努力了解影响应计利润的因素，特别是特殊人群(如少数群体、老年人、经济困难群体)的因素，并在可能的情况下采取适当的干预措施。